000165107 001__ 165107
000165107 005__ 20230915090605.0
000165107 0247_ $$2doi$$a10.3389/fncel.2022.788150
000165107 0247_ $$2pmid$$apmid:35910248
000165107 0247_ $$2pmc$$apmc:PMC9329528
000165107 0247_ $$2altmetric$$aaltmetric:133170675
000165107 037__ $$aDZNE-2022-01416
000165107 041__ $$aEnglish
000165107 082__ $$a610
000165107 1001_ $$aPolyakova, Maryna$$b0
000165107 245__ $$aIncreased Serum NSE and S100B Indicate Neuronal and Glial Alterations in Subjects Under 71 Years With Mild Neurocognitive Disorder/Mild Cognitive Impairment.
000165107 260__ $$aLausanne$$bFrontiers Research Foundation$$c2022
000165107 3367_ $$2DRIVER$$aarticle
000165107 3367_ $$2DataCite$$aOutput Types/Journal article
000165107 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1664540963_12113
000165107 3367_ $$2BibTeX$$aARTICLE
000165107 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165107 3367_ $$00$$2EndNote$$aJournal Article
000165107 520__ $$aMild cognitive impairment (MCI) is considered a pre-stage of different dementia syndromes. Despite diagnostic criteria refined by DSM-5 and a new term for MCI - 'mild neurocognitive disorder' (mild NCD) - this diagnosis is still based on clinical criteria.To link mild NCD to the underlying pathophysiology we assessed the degree of white matter hyperintensities (WMH) in the brain and peripheral biomarkers for neuronal integrity (neuron-specific enolase, NSE), plasticity (brain-derived neurotrophic factor, BDNF), and glial function (S100B) in 158 community-dwelling subjects with mild NCD and 82 healthy controls. All participants (63-79 years old) were selected from the Leipzig-population-based study of adults (LIFE).Serum S100B levels were increased in mild NCD in comparison to controls (p = 0.007). Serum NSE levels were also increased but remained non-significant after Bonferroni-Holm correction (p = 0.04). Furthermore, age by group interaction was significant for S100B. In an age-stratified sub-analysis, NSE and S100B were higher in younger subjects with mild NCD below 71 years of age. Some effects were inconsistent after controlling for potentially confounding factors. The discriminatory power of the two biomarkers NSE and S100B was insufficient to establish a pathologic threshold for mild NCD. In subjects with mild NCD, WMH load correlated with serum NSE levels (r = 0.20, p = 0.01), independently of age.Our findings might indicate the presence of neuronal (NSE) and glial (S100B) injury in mild NCD. Future studies need to investigate whether younger subjects with mild NCD with increased biomarker levels are at risk of developing major NCD.
000165107 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000165107 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000165107 650_7 $$2Other$$aBDNF
000165107 650_7 $$2Other$$aBrain-Derived Neurotrophic Factor
000165107 650_7 $$2Other$$aNSE
000165107 650_7 $$2Other$$aS100B
000165107 650_7 $$2Other$$amild cognitive impairment
000165107 650_7 $$2Other$$aneuron-specific enolase
000165107 650_7 $$2Other$$awhite matter hyperintensities
000165107 7001_ $$aMueller, Karsten$$b1
000165107 7001_ $$aArelin, Katrin$$b2
000165107 7001_ $$aLampe, Leonie$$b3
000165107 7001_ $$0P:(DE-2719)9000725$$aRodriguez, Francisca S$$b4$$udzne
000165107 7001_ $$aLuck, Tobias$$b5
000165107 7001_ $$aKratzsch, Jürgen$$b6
000165107 7001_ $$aHoffmann, Karl-Titus$$b7
000165107 7001_ $$aRiedel-Heller, Steffi$$b8
000165107 7001_ $$aVillringer, Arno$$b9
000165107 7001_ $$aSchoenknecht, Peter$$b10
000165107 7001_ $$aSchroeter, Matthias L$$b11
000165107 773__ $$0PERI:(DE-600)2452963-1$$a10.3389/fncel.2022.788150$$gVol. 16, p. 788150$$p788150$$tFrontiers in cellular neuroscience$$v16$$x1662-5102$$y2022
000165107 8564_ $$uhttps://pub.dzne.de/record/165107/files/DZNE-2022-01416.pdf$$yOpenAccess
000165107 8564_ $$uhttps://pub.dzne.de/record/165107/files/DZNE-2022-01416.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000165107 909CO $$ooai:pub.dzne.de:165107$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000165107 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000725$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000165107 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000165107 9141_ $$y2022
000165107 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000165107 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000165107 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000165107 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000165107 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000165107 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000165107 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000165107 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT CELL NEUROSCI : 2021$$d2022-11-25
000165107 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000165107 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000165107 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-13T10:30:24Z
000165107 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-13T10:30:24Z
000165107 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-13T10:30:24Z
000165107 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000165107 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000165107 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000165107 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2022-11-25
000165107 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT CELL NEUROSCI : 2021$$d2022-11-25
000165107 9201_ $$0I:(DE-2719)1713001$$kAG Rodriguez-Muela$$lSelective Neuronal Vulnerability in Neurodegenerative Diseases$$x0
000165107 980__ $$ajournal
000165107 980__ $$aVDB
000165107 980__ $$aUNRESTRICTED
000165107 980__ $$aI:(DE-2719)1713001
000165107 9801_ $$aFullTexts